Gene activations of CYP2B1 and CYP3A1 by dihydropyridine calcium channel antagonists in the rat liver: The structure-activity relationship

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 6, 2004, Pages 903-905

  Konno, Yoshihiro ^a   Degawa, Masakuni ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Calcium channel antagonist; CYP2B1; CYP3A1; P450 induction; Rat liver; Structure activity relationship

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2B1; CYTOCHROME P450 3A1; DIHYDROPYRIDINE DERIVATIVE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; CYP3A1 PROTEIN, RAT; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE ACTIVATION; LIVER; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TRANSACTIVATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP2B1; DIHYDROPYRIDINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIVER; MALE; RATS; RATS, INBRED F344; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS);

EID: 8444242511     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.903     Document Type: Article

References (13)

1. Schlanz K. D., Myre S. A., Bottorff M. B., Clin. Pharmacokinet., 21, 344-356 (1991).
2. Rosenthal T., Ezra D., Drug Safety, 13, 157-187 (1995).
3. Campana C., Regazzi M. B., Buggia I., Molinaro M., Clin. Pharmacokinet., 30, 141-179 (1996).
4. Bertz R. J., Granneman G. R., Clin. Pharmacokinet., 32, 210-258 (1997).
5. Pichard L., Fabre I., Fabre G., Domergue J., Saint A. B., Mourad G., Maurel P., Drug Metab. Dispos., 18, 595-606 (1990).
6. Ma B., Prueksaritanont T., Lin J. H., Drug Metab. Dispos., 28, 125-130 (2000).
7. Zangar R. C., Okita J. R., Kim H., Thomas P. E., Anderson A., Edwards R. J., Springer D. L., Okita R. T., J. Pharmacol. Exp. Ther., 290, 1436-1441 (1999).
8. Konno Y., Nemoto K., Degawa M., Xenobiotica, 33, 119-129 (2003).
9. Konno Y., Sekimoto M., Nemoto K., Degawa M., Toxicol. Appl. Pharmacol., 196, 20-28 (2004).
10. Drocourt L., Pascussi J.-M., Assenat E., Fabre J.-M., Maurel P., Vilarem M.-J., Drug Metab. Dispos., 29, 1325-1331 (2001).
11. Omiecinski C. J., Hassett C., Costa P., Mol. Pharmacol., 38, 462-470 (1990).
12. Oinonen T., Lindros K. O., Biochem. J., 309, 55-61 (1995).
13. Nemoto K., Miyata S., Nemoto F., Yasumoto T., Murai U., Kageyama H., Degawa M., Biochem. Biophys. Res. Commun., 275, 472-476 (2000).